USNA has been the subject of a number of other reports. BidaskClub raised USANA Health Sciences from a sell rating to a hold rating in a report on Thursday, October 26th. Pivotal Research lifted their price target on USANA Health Sciences from $70.00 to $80.00 and gave the company a buy rating in a report on Wednesday, October 25th. Finally, Sidoti cut USANA Health Sciences from a buy rating to a neutral rating in a report on Wednesday, January 24th.
USANA Health Sciences (NYSE USNA) opened at $74.20 on Tuesday. The stock has a market capitalization of $1,697.47, a price-to-earnings ratio of 29.44 and a beta of 0.99. USANA Health Sciences has a twelve month low of $52.55 and a twelve month high of $79.00.
In related news, Director Myron W. Wentz sold 38,223 shares of USANA Health Sciences stock in a transaction dated Tuesday, February 6th. The stock was sold at an average price of $71.51, for a total value of $2,733,326.73. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Myron W. Wentz sold 5,304 shares of USANA Health Sciences stock in a transaction dated Monday, November 13th. The shares were sold at an average price of $66.01, for a total value of $350,117.04. Following the completion of the transaction, the director now directly owns 12,011,418 shares of the company’s stock, valued at $792,873,702.18. The disclosure for this sale can be found here. Insiders sold 433,455 shares of company stock valued at $28,990,246 over the last ninety days. 53.20% of the stock is currently owned by company insiders.
A number of large investors have recently made changes to their positions in USNA. JPMorgan Chase & Co. raised its holdings in USANA Health Sciences by 2.1% during the 2nd quarter. JPMorgan Chase & Co. now owns 16,385 shares of the company’s stock worth $1,050,000 after purchasing an additional 341 shares during the last quarter. Ameriprise Financial Inc. raised its holdings in USANA Health Sciences by 6.0% during the 2nd quarter. Ameriprise Financial Inc. now owns 47,228 shares of the company’s stock worth $3,027,000 after purchasing an additional 2,665 shares during the last quarter. Nationwide Fund Advisors raised its holdings in USANA Health Sciences by 7.5% during the 2nd quarter. Nationwide Fund Advisors now owns 6,589 shares of the company’s stock worth $422,000 after purchasing an additional 457 shares during the last quarter. New York State Common Retirement Fund raised its holdings in USANA Health Sciences by 1.2% during the 2nd quarter. New York State Common Retirement Fund now owns 32,534 shares of the company’s stock worth $2,085,000 after purchasing an additional 370 shares during the last quarter. Finally, Northern Trust Corp raised its holdings in USANA Health Sciences by 10.5% during the 2nd quarter. Northern Trust Corp now owns 177,630 shares of the company’s stock worth $11,386,000 after purchasing an additional 16,948 shares during the last quarter. 44.26% of the stock is owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION NOTICE: This report was posted by Community Financial News and is the property of of Community Financial News. If you are reading this report on another publication, it was illegally stolen and republished in violation of US and international trademark & copyright law. The original version of this report can be accessed at https://www.com-unik.info/2018/02/09/thestreet-downgrades-usana-health-sciences-usna-to-c.html.
About USANA Health Sciences
USANA Health Sciences, Inc develops and manufactures science-based nutritional and personal care products. The Company operates as a direct selling company in two geographic regions: Americas and Europe, and Asia Pacific, which includes three sub-regions: Southeast Asia Pacific, Greater China and North Asia.
Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.